With staff losses resulting from the European Medicines Agency's relocation to the Netherlands likely to be higher than expected, the EMA says it plans to further re-prioritize its activities this year and next in order to maintain its core regulatory functions “as far as possible.”
An internal survey carried out by the agency in 2017 showed that 81% of staff would be willing to move...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?